Sunitinib in metastatic renal cell carcinoma patients with brain metastases. - Wikidata - awgldk - TriplyDB

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

http://www.wikidata.org/entity/Q33391978

about

Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases Chinese guidelines on the management of renal cell carcinoma (2015 edition)Individualising treatment choices in a crowded treatment algorithm Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data.Metastatic cerebellar gastrointestinal stromal tumor with obstructive hydrocephalus arising from the small intestine: a case report and review of the literature Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.Early identification of asymptomatic brain metastases from renal cell carcinoma.Experience with sunitinib in the treatment of metastatic renal cell carcinoma Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.Innovative therapeutic strategies in the treatment of brain metastases.Induction of apoptosis by luteolin involving akt inactivation in human 786-o renal cell carcinoma cells The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.Targeted therapies in brain metastases.Chemoprevention for brain metastases.Treatment of brain metastases: chemotherapy.Sunitinib malate for the treatment of renal cell carcinoma.Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.Antiangiogenic therapy in the management of brain tumors: a clinical overview.Treating patients with metastatic renal carcinoma: an escape from Phase III.Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy.The ineligible patient: how to treat patients not included in clinical studies.Biology in prevention and treatment of brain metastases.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Brain metastases: an overview.The future of targeted therapies for brain metastases.Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors.Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.Sunitinib Possible Sex-Divergent Therapeutic Outcomes.Synthetic miR-145 Mimic Enhances the Cytotoxic Effect of the Antiangiogenic Drug Sunitinib in Glioblastoma.Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO).Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma.Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?Sunitinib treatment for multiple brain metastases from jejunal gastrointestinal stromal tumor: case report.Pazopanib-Induced Regression of Brain Metastasis After Whole Brain Palliative Radiotherapy in Metastatic Renal Cell Cancer Progressing on First-Line Sunitinib: A Case Report.

P2860

Q26768667-41CFA9B8-EE0D-4B9A-BDE7-1367599730A0 Q26772206-98A999F8-9AD9-4E44-9240-3BC509D05B75 Q27023669-1E30DEB2-C497-4CF4-8644-B43756396936 Q28077050-140BCC6B-9493-4CDC-A7C3-35B2B86B99C6 Q30382892-AEBD3A97-3484-46F7-B98A-39E6B480AA72 Q30557877-BA0180B8-01A9-49FF-9D98-D4645C5A1F65 Q30885557-7B400D35-0AAF-4826-8A53-D2B13F9A66FB Q33396181-DBD0D813-EF88-4DF5-8353-93F05122349D Q34607538-1CCE5601-7D40-499E-B89F-1DC73C798923 Q35743315-64141E90-890C-425F-89C7-8A8EB0C05EB2 Q35800847-74385C1E-6378-4CBE-ADC3-084A944764FB Q36231729-11BD433E-6006-4C76-8A32-E713FBA94334 Q36384503-24B8E2F7-B75D-4492-AB26-8D9415FDBF4A Q36590195-C58F7BF9-7801-41F1-8E91-7C51155D9DD3 Q36622608-FCA3B303-3487-483E-9108-736F5B3FF39B Q37217773-BE77E7A2-5478-4D26-B257-591109E8FBDE Q37354135-D33FB4DB-5AA6-4985-9ACB-AFF7CD9A918E Q37491460-E388CC5F-D163-446A-90D6-6A773FC4D2AF Q37946748-1B9007AA-CCAE-43BE-AC36-A48F7B022809 Q37967507-3343FF10-ED0A-4954-9A29-773F3BFD67AB Q38011201-902EA244-8EDA-4AD1-8ED6-28905747E388 Q38028411-A733B7ED-DEEE-496F-8BA7-B1D169F788E1 Q38028766-E41635DF-019D-4BF4-B066-186BCBB8BF23 Q38030592-B9B02266-ABBF-4C73-871B-2A22CD2010F3 Q38081808-16D8A12B-DFDD-4A47-983C-92A5F8E7BABA Q38084204-00A0A009-CCFD-4E49-955D-4354DE9F1EDF Q38156192-E8D04BE9-EC0E-4E87-9A39-F7D604EE17AF Q38171327-F775F494-7A48-47CD-9937-CA0D5EB1A1D8 Q38317417-AEF71FCC-E689-4959-914C-EA05E5315127 Q38564085-DDA5DD7B-466D-4A76-B331-DAAE15FB56C6 Q38715328-9B28E241-27DF-4A4F-92FD-7F48FB4A264D Q38823987-E9300B88-9D19-43F7-A794-676358089E3A Q38869600-2C25B963-A0F1-42E3-B39A-D045E8AF4497 Q38922566-25327E61-716E-4BA1-B776-F1575A7356DD Q39229266-D1073BEC-46D3-4EAB-A17E-DBDF1B79673E Q39476399-8B5CC61A-F362-40F6-9FD8-F56ED401F904 Q39505003-CC291A9B-5082-4D3F-8B96-5D74B982B92E Q41781423-C6E1EE96-2A26-4832-9D87-F59535147359 Q42137803-EF839CC0-0B8B-4A70-AE97-7BA24AF6DD66 Q47094664-CF3638F3-E22E-4649-AF40-18BB6D6C5EF2

P2860

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

http://www.wikidata.org/entity/Q33391978

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@ast

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@en

type

label

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@ast

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@en

prefLabel

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@ast

Sunitinib in metastatic renal cell carcinoma patients with brain metastases.

@en

P1433

Q33391978-7634724B-AD94-400B-A72B-CCB118C5B73B

P1476

Q33391978-52AD8455-B64B-4F09-A56F-A3946D1BC3FD

P2093

Q33391978-185C6383-B49E-4C6E-9EB8-06586DEE9969

Q33391978-1D84C314-D71B-4EB1-B4F8-95AA2D6DF43F

Q33391978-46168321-0262-47C3-8767-742FBCF81D74

Q33391978-4C5A6F39-F8DC-4368-B704-E02F31977D98

Q33391978-8FBF6773-E8CC-442C-B663-8EDEA444B8A3

Q33391978-CA68BC92-02ED-493F-8C28-E55E8FA0A07D

Q33391978-F8586241-B7E2-411B-8586-4C17A4F3B2A4

Q33391978-FD533536-E796-4F4A-94D9-1905C75E1CD4

P2860

Q33391978-00D9DAE4-C89E-4A23-A817-B455AA6D3698

Q33391978-0B165012-CF0C-44ED-87AA-8352F034E35D

Q33391978-20015E5E-F9FB-41BE-A4CF-0CA1AE2B0401

Q33391978-59EF5C61-1022-4AF5-9E0F-C1F00FFE9A04

Q33391978-5A2F876C-4EA1-4FB1-B717-4A8B52924EEE

Q33391978-5BC011D5-B590-4674-8F27-C402708AA2EC

Q33391978-832A6313-A296-43C2-85E6-01CD9898EF63

Q33391978-856BC2C5-324A-483E-8FB7-A8D990F95693

Q33391978-A2FEC576-FF85-405B-BEF4-9C170998F9FD

Q33391978-CA35C852-2CF5-4738-941B-2654360BEDCB

P304

Q33391978-80F1AA84-F4DF-4385-9DE6-267A5BC58498

P31

Q33391978-DEFDD7B2-5D63-4CDA-A41C-BCD0AA48D1F0

P356

Q33391978-9EF7CAC0-DC6D-4DE8-A90F-14BB875F45EB

P407

Q33391978-DCA77F8A-BE39-4BD2-95D1-1878D531795E

P433

Q33391978-91D3D2AA-2012-4CC0-ADDC-83E67572CBF0

P478

Q33391978-39AC947A-660B-4BBF-8367-324736B1D9AA

P50

Q33391978-0DDD0408-1B1F-4ED2-94E4-3865D3CD9496

Q33391978-5FF3AEA0-ABA5-404C-A836-849628CFD130

Q33391978-769473C9-27B6-45A1-8B4C-05C4403B882C

Q33391978-E201D8DC-B5CA-49D2-8D91-49CE32744FC1

P577

Q33391978-B17A82DC-690B-40A9-AEA0-EF360CADCACF

P5875

Q33391978-9B5DC7C0-B8C4-478A-948C-3F0EFBE2ED2C

P698

Q33391978-D6A74E97-9B0A-4DAF-A216-44274113B979

P356

P1433

P1476

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

@en

P2093

Alejandra Nieto

http://www.w3.org/2001/XMLSchema#string

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Jinyu Yuan

http://www.w3.org/2001/XMLSchema#string

Martin E Gore

http://www.w3.org/2001/XMLSchema#string

Robert Hawkins

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Stéphane Oudard

http://www.w3.org/2001/XMLSchema#string

Subramanian Hariharan

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Sunitinib in patients with metastatic renal cell carcinoma.

Sunitinib: from rational design to clinical efficacy.

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

P304

501-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25452

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

Georg A. Bjarnason

Giacomo Cartenì

P577

2010-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46404772

http://www.w3.org/2001/XMLSchema#string

P698

20862748

http://www.w3.org/2001/XMLSchema#string